PROGNOSTIC VALUE OF MIR-29C IN BREAST, CERVICAL, ENDOMETRIAL, AND OVARIAN CANCER

微小核酸-29c於乳癌、子宮頸癌、子宮內膜癌和卵巢癌之預後價值

10.3966/156104972021122002002

蘇峻民(Jimmy Chun-Min Su)；林宏昱(Hung-Yu Lin)

Breast cancer ； Cervical cancer ； Endometrial cancer ； Uterine carcinosarcomas ； Ovarian cancer ； Microrna-29c ； Prognostic biomarkers ； 乳癌 ； 子宮頸癌 ； 子宮內膜癌 ； 子宮癌惡性肉瘤 ； 卵巢癌 ； 微小核酸-29c ； 預後生物指標

秀傳醫學雜誌

20卷2期（2021 / 12 / 01）

68 - 79

英文

Breast cancer (BC) and gynecological cancers including cervical cancer (CC), endometrial cancer (EC), uterine carcinosarcomas (UCS), and ovarian cancer (OC) are a leading cause of death globally. In Taiwan, breast cancer and gynecological cancers account for the highest mortality in women suffering from cancer. The tumor-regulatory role of microRNA (miR)-29c has been reported. However, the prognostic value of miR-29c in breast cancer and gynecological cancers remains uncertain. In this study, we performed Cancer Genome Atlas (TCGA) data-mining via UALCAN to determine whether miR-29c expression levels can serve as a predictive marker. Expression levels of miR-29c were surveyed. Survival analysis between patient groups harboring high and low expression of miR-29c were analyzed. miR-29c expression showed no statistical difference between normal and BC tumor tissue. BC with HER2-positive and triple negative (TNBC) showed lower miR-29c expression levels than that of the luminal subtype. BC patients harboring low expression of miR-29c demonstrated shorter survival time than those with high expression of miR-29c. miR-29c expression showed no statistical difference between normal and CC tumor tissue. CC tissue of stage 4 had lower miR-29c expression levels than that of stage 3. Notably, CC patients harboring low expression of miR-29c demonstrated shorter survival time than those with high expression of miR-29c. With regard to EC, miR-29c expression exhibited a statistical difference between normal and EC tumor tissue. EC tissue from young aged patients showed higher value of miR-29c expression than that in older aged patients. Furthermore, EC patients harboring low expression of miR-29c presented reduced survival time as compared those harboring high expression of miR- 29c. Interestingly, we noted that another type of uterus cancer, uterine carcinosarcomas (UCS), expressed higher miR-29c levels in older aged patients and miR-29c high expression predicted reduced survival time. In OC, miR-29a expression levels of the oldest cohort were lower than those of young groups. Low expression of miR-29c indicated poor survival rate. We conclude that low expression of miR-29c can predict poor survival rate in patients with BC, CC, EC, UCS, and OC.

乳癌（BC）和婦科癌包括子宮頸癌（CC），子宮內膜癌（EC）和卵巢癌（OC）是全球主要的死亡原因。在台灣，乳癌和婦科癌症是女性罹患癌症的最高死亡率。微小核酸（miR）-29c已知具有腫瘤調節作用。但是，miR-29c在乳腺癌和婦科癌症中的預後價值仍然不確定。在這項研究中，我們存取UALCAN以進行《癌症基因組圖譜》（TCGA）數據挖掘，確定miR-29c表達水平是否可以用作預測標記。研究調查miR-29c的表達水平，分析高表達和低表達miR-29c的患者組之間的生存分析。miR-29c表達在正常和BC腫瘤組織之間無統計學差異。帶有HER2陽性和三陰性的BC（TNBC）的miR-29c表達水平低於管腔亞型。攜帶低表達miR-29c的BC患者比那些高表達miR-29c的患者俱有更短的生存時間。miR-29c表達在正常和CC腫瘤組織之間無統計學差異。第四期CC組織的miR-29c表達水平低於第三期CC組織。值得注意的是，具有低表達miR-29c的CC患者的生存時間短於具有高表達miR-29c的CC患者。關於EC，miR-29c表達在正常和EC腫瘤組織之間表現出統計學差異。青年時期的EC組織顯示出比老年時期更高的miR-29c表達值。此外，與那些高表達miR-29c的EC患者相比，那些低表達miR-29c的EC患者的生存時間縮短。有趣的是，子宮癌惡性肉瘤（UCS）則是在較老患者表現量高於年輕者，且miR-29c高表達量預測生存時間縮短。在OC中，年齡最大的人群的miR-29a表達水平低於年輕人組。miR-29c的低表達表明存活率低。我們得出的結論是，低表達miR-29c可以預測BC，CC，EC和OC患者的不良生存率，在UCS則是高表達miR-29c。